Author/Authors :
Dewald، نويسنده , , Gordon and Stallard، نويسنده , , Richard and Alsaadi، نويسنده , , A. and Arnold، نويسنده , , Susan and Blough، نويسنده , , Ruthann and Ceperich، نويسنده , , Tina M. and Elejalde، نويسنده , , B.Rafael and Fink، نويسنده , , James and Higgins، نويسنده , , James V. and Higgins، نويسنده , , Rodney R. and Hoeltge، نويسنده , , Gerald A. and Hsu، نويسنده , , Wei-Tong and Johnson، نويسنده , , Eric، نويسنده ,
Abstract :
Twenty-eight laboratories evaluated a new fluorescence in situ hybridization (FISH) strategy for chronic myeloid leukemia. In a three-part study, bcr/abl1 D-FISH probes were used to study bone marrow specimens. First, laboratories familiarized themselves with the strategy by applying it to known normal and abnormal specimens. Then, collectively the laboratories studied 20 normal and 20 abnormal specimens blindly and measured workload. Finally, each laboratory and two experts studied six serial dilutions with 98–0% abnormal nuclei. Using the reported normal cutoff of <1% abnormal nuclei, participants reported no false-negative cases and 15 false-positive cases (1–6.6% abnormal nuclei). Results provided by participants for serial dilutions approximated the expected percentages of abnormal nuclei, but those from the experts exhibited greater precision. The clinical sensitivity, precision, nomenclature, workload, recommendations for training, and quality assurance in methods using D-FISH in clinical practice are discussed.
